Zevra Therapeutics (NASDAQ:ZVRA) Upgraded to "Strong-Buy" at Cantor Fitzgerald

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating in a research note issued to investors on Wednesday,Zacks.com reports.

A number of other analysts also recently weighed in on ZVRA. Guggenheim initiated coverage on shares of Zevra Therapeutics in a research report on Monday, October 7th. They set a "buy" rating and a $20.00 target price for the company. Canaccord Genuity Group decreased their target price on Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday, November 14th. Finally, HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $21.57.

Zevra Therapeutics Price Performance

Shares of NASDAQ:ZVRA traded up $0.18 during trading on Wednesday, reaching $8.04. 774,219 shares of the company traded hands, compared to its average volume of 413,970. The firm has a market capitalization of $428.91 million, a PE ratio of -4.08 and a beta of 2.01. The company's 50 day moving average is $8.58 and its two-hundred day moving average is $7.92. Zevra Therapeutics has a 52 week low of $4.20 and a 52 week high of $9.76. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.25). The company had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same period last year, the company posted ($0.40) EPS. As a group, sell-side analysts predict that Zevra Therapeutics will post -1.95 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ZVRA. International Assets Investment Management LLC increased its holdings in Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company's stock worth $48,000 after purchasing an additional 5,940 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company's stock worth $91,000 after buying an additional 2,452 shares in the last quarter. Hunter Associates Investment Management LLC purchased a new stake in Zevra Therapeutics in the 3rd quarter valued at $92,000. XTX Topco Ltd bought a new position in Zevra Therapeutics during the 3rd quarter valued at $94,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in Zevra Therapeutics during the 4th quarter valued at $94,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.